Clinuvel Pharmaceuticals Limited, Annual General Meeting, Nov 18, 2009, at 10:00 EAST-East Australian Standard GST. Location: Condell Room of the Melbourne Town Hall,Australia.

Clinuvel Pharmaceuticals Limited reported consolidated and company earnings results for the full year ended June 30, 2009. For the consolidated, the company reported net loss, loss before income tax expense and loss after income tax expenses of AUD 15,372,907 or 5.1 cents per basic share on revenues of AUD 2,904,917 for the full year ended June 30, 2009 against net loss, loss before income tax expense and loss after income tax expenses of AUD 14,655,791 or 4.8 cents per basic share on revenues of AUD 4,297,103 in the same period of last year. Net cash used in operating activities was AUD 10,985,544 against AUD 7,181,333 in the same period of last year. Payments for property, plant and equipment was AUD 32,454 against AUD 221,106 in the same period of last year. For the full year ended June 30, 2009, the company reported net loss, loss before income tax expense and loss after income tax expenses of AUD 15,366,377 on revenues of AUD 2,904,789 against net loss, loss before income tax expense and loss after income tax expenses of AUD 14,645,068 on revenues of AUD 4,296,376 in the same period of last year. Net cash used in operating activities was AUD 9,194,364 against AUD 6,288,423 in the same period of last year. Payments for property, plant and equipment was AUD 9,744 against AUD 171,489 in the same period of last year.

Clinuvel Pharmaceuticals Limited reported preliminary return on equity for the year ended June 30, 2009. The company reported negative return on equity of 41.5% and negative return on assets of 36.9% compared to negative return on equity of 28.3% and negative return on assets of 26.7% for the same period last year.